EBITDA (including other revenue) was at Rs 141.6 crore in Q4 FY23 from Rs 96.9 crore in Q4 FY22, registering the growth of 46% year on year. EBITDA margin reduced to 28% in Q4 FY23 from 31% in Q4 FY22.

Operating revenue jumped 48% year on year to Rs 480 crore in Q4 FY23.

On full year basis, the company's consolidated net profit increased by 18.84% to Rs 180.84 crore on 49.19% jump in revenue from operations to Rs 1,601.9 crore in FY23 over FY22.

The board has declared third interim dividend of Rs 1.50 per equity share for FY23. The record date for payment of dividend is fixed on 15 May 2023 and payment date on or before 1 June 2023.

Speaking on the performance, Anand Desai, managing director, Anupam Rasayan commented, “We have continued our growth momentum with a 49% YoY revenue growth on the back of new products commercialized during the year as well as steady growth of the organic portfolio.

On the operations part, we continue to focus on adding more value-added products in our basket as well as bringing financial efficiencies. We have already started witnessing the results of the same which is visible in stable margins and improved working capital resulting in strong cash generation of Rs 2,440 Million from operations.

As we stand, we have signed contracts and LOIs of Rs 54,830 Million giving us a strong revenue visibility for the coming years. At the same time, we are witnessing a robust traction in customer engagement as we remain in advance stage of discussions with customers across geographies for many niche and high value molecules. All these factors give us a reassurance of sustained robust growth in FY24.”

Anupam Rasayan India is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Its business verticals are life science related specialty chemicals comprising products related to agrochemicals, personal care and pharmaceuticals, and other specialty chemicals, comprising specialty pigment and dyes, and polymer additives.